Investor Presentaiton
Hematology
Cell Therapy
Immunology
Cardiovascular
Oncology
Opdualag (anti-LAG3 + anti-PD1 FDC)
Indication
Phase/Study
# of Patients
Adjuvant Melanoma
Phase III - RELATIVITY-098
N = 1050
Relatlimab + nivolumab FDC 160
Design
mg/480 mg Q4W
Nivolumab 480mg Q4W
Primary: RFS
Key secondary: OS
Endpoints
Status
CT Identifier
1L Melanoma SC
Phase III - RELATIVITY-127
N = 814
Relatlimab + nivolumab + rHuPH20 FDC SC
•
Relatlimab + nivolumab FDC IV
Primary:
•
Cavgd28 of nivolumab; Cminss of nivolumab
Cavgd28 of relatlimab; Cminss of relatlimab
Key secondary: ORR
2L/3L+ MSS MCRC
Phase III RELATIVITY-123
N = 700
Relatlimab nivolumab FDC
Investigator's Choice: regorafenib or TAS-102
(trifluridine/tipiracil)
Primary:
• OS in PD-L1 CPS≥1
•
OS in all-comers
Key secondary: ORR
Projected data readout 2025
Projected data readout 2026
•
Recruiting
•
Projected data readout 2025
NCT05002569
ll Bristol Myers Squibb Q3 2023 Results
NCT05625399
NCT05328908
Not for Product Promotional Use
36View entire presentation